Clinical trials: Metastatic Malignant Neoplasm to Brain
Carcinoma, Non-Small-Cell Lung, Brain Neoplasms
Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II Trial
This is an open-label, randomized, multicenter phase II study conducting in 3 medical centers in Asia. Patients will receive erlotinib in combination with bevacizumab or erlotinib alone.
- Trial name
- BRILLIANT (NCT02655536)
- Testing
- Bevacizumab plus erlotinib, Erlotinib
- Where
- Taiwan
- Volunteers
- 109 people
- Sponsor
- National Taiwan University Hospital
Brain Metastases, Adult Solid Tumor
Cyberknife Radiosurgery for Patients With Brain Metastases Diagnosed With Either SPACE or MPRAGE Sequence
For patients with cerebral oligometastases who are in adequate clinical condition stereotactic radiosurgery (SRS) is the treatment of choice, being recommended by international guidelines for the treatment of one to four lesions.
- Trial name
- CYBER-SPACE (NCT03303365)
- Testing
- stereotactic radiosurgery (SRS)
- Where
- Germany
- Volunteers
- 203 people
- Sponsor
- Juergen Debus
Neoplasm Metastasis
Whole Brain Radiotherapy (WBRT) Versus Stereotactic Radiosurgery (SRS) for 4 Upto 10 Brain Metastases
Recently stereotactic radiosurgery (SRS) in 5 up to 10 brain metastases showed to have equal survival as in 2 up to 4 brain metastases.
- Trial name
- WBRTvsSRS (NCT02353000)
- Testing
- Stereotactic Radiosurgery, Whole Brain Radiotherapy
- Where
- 7 sites in Netherlands
- Volunteers
- 31 people
- Sponsor
- Maastricht Radiation Oncology
Central Nervous System Cancer, Brain Metastases
Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1
Adult patients with primary or secondary central nervous system malignancies will be invited to undergo a baseline [C-11]-CS1P1 PET scan and a follow-up scan within 24 months of the baseline scan (preferably within 6-months…
- Trial name
- NCT07462507
- Testing
- [C-11]-CS1P1, Brain MRI
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Washington University School of Medicine
Non Small Cell Lung Cancer, Brain Metastases, Adult
Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases
This is an open-label, non-randomised, phase II, multicenter clinical trial. 71 stage IV or recurrent, non-small cell lung cancer patients with synchronous brain metastases will be enrolled in this trial to evaluate the efficacy…
- Conditions
- Non Small Cell Lung Cancer, Brain Metastases, Adult, Lung Cancer
- Trial name
- NIVIPI-Brain (NCT05012254)
- Testing
- Ipilimumab, Nivolumab, Carboplatin
- Where
- 18 sites in Spain
- Volunteers
- 71 people
- Sponsor
- Fundación GECP
Triple Negative Breast Cancer (TNBC), Brain Metastasases
JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases
This study was designed to evaluate the safety, efficacy and pharmacokinetics of JK-1201I in triple negative breast cancer patients with brain metastases.
- Trial name
- NCT06586866
- Testing
- JK-1201I
- Volunteers
- 25 people
- Sponsor
- JenKem Technology Co., Ltd.
Brain Metastases, HER2-positive Breast Cancer
Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer
This research study will evaluate how well brain metastases associated with HER-2 positive breast cancer can be controlled using a type of radiation known as stereotactic radiosurgery (SRS) when combined with three therapeutic…
- Trial name
- NCT05553522
- Testing
- Combined use of SRS with Tucatinib, Trastuzumab, and Capecitabine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Baptist Health South Florida
Brain Metastases, Cancer (With CNS Involvement)
Brain Metastases in Greater Size - Hypofractionated Options Trial (BIGSHOT)
This is a randomized, phase II trial comparing staged stereotactic radiosurgery (SSRS) versus fractionated stereotactic radiotherapy (FSRT) in patients with large brain metastases (≥2 cm and ≤5 cm).
- Trial name
- NCT07227610
- Testing
- Staged Stereotactic Radiosurgery (SSRS), Fractionated Stereotactic Radiotherapy (FSRT)
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Medical University of South Carolina
Brain Metastases
Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases
In this dose-escalation study, the safety and tolerability of escalating dose levels of RRx-001 administered intravenously twice a week in subjects with brain metastases receiving whole brain radiation therapy (WBRT) will be…
- Trial name
- BRAINSTORM (NCT02215512)
- Testing
- RRx-001 + WBRT
- Where
- 5 sites in United States
- Volunteers
- 29 people
- Sponsor
- EpicentRx, Inc.
Metastatic Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain
Stereotactic Radiosurgery or Whole Brain Radiation Therapy in Treating Patients With Newly Diagnosed Non-melanoma Brain Metastases
This randomized phase III clinical trial compares stereotactic radiosurgery with whole brain radiation therapy to see how well they work in treating patients with non-melanoma cancer that has recently spread from the first…
- Trial name
- NCT01592968
- Testing
- Cognitive Assessment, Quality-of-Life Assessment, Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma
Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)
Substudy 02D is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study.
- Trial name
- NCT04700072
- Testing
- Pembrolizumab, Pembrolizumab/Quavonlimab, Lenvatinib
- Where
- 36 sites in United States, Australia and 6 more
- Volunteers
- 56 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer
A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain
Our hypothesis is that this study design, in which bevacizumab is added to one of six single agent chemotherapies with proven activity in metastatic breast cancer, will result in regression or stabilization of this disease in a…
- Trial name
- NCT00476827
- Testing
- Bevacizumab, Docetaxel, CPT-11
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Duke University
Pelvic Fracture, Prostate Cancer
A COhort Study on Factors Leading to Vulnerability in Adult Patients With Serious Medical cOnditionS: the COSMOS-I Trial
The objective of this prospective multicentre study that recruits altogether 1500 older patients from the university hospitals of Tampere, Kuopio, and Oulu is to explore the clinical significance and detection of causes of…
- Conditions
- Pelvic Fracture, Prostate Cancer, Lung Cancer, Brain Metastasis
- Trial name
- COSMOS-I (NCT07740239)
- Testing
- Test set to determine vulnerability
- Where
- Finland
- Volunteers
- 2,050 people
- Sponsor
- Tampere University Hospital
Brain Cancer
Randomized Trial Comparing Radiosurgery With vs Without Whole Brain Radiotherapy
The goal of this clinical research study is to learn if your thinking ability (cognitive function) will be better preserved by delivering whole brain radiation therapy immediately after radiosurgical treatment of 1-3 brain…
- Trial name
- NCT00548756
- Testing
- Whole Brain Radiation Therapy, Observation, Questionnaire
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer
Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases
Patients will receive AZD9291 at a dose of 80 mg once daily. Intracranial response will be assessed with brain MRI scan, systemic evaluation will be done by PET-CT (Positron Emission Tomography-Computed Tomography) scan.
- Trial name
- NCT02736513
- Testing
- AZD9291
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Soroka University Medical Center
Metastasis Brain
Stereotactic Radiotherapy for Brain Metastases
Stereotactic radiotherapy is an innovative treatment enabling to target accurately brain metastases. The aim of this study is to evaluate tumoral response and acute and late toxicity of this treatment.
- Trial name
- CKBrainMeta (NCT03286023)
- Testing
- stereotactic radiotherapy
- Where
- Luxembourg
- Volunteers
- 110 people
- Sponsor
- Centre Francois Baclesse, Luxembourg
Brain Metastasis, Cancer
Neuropsychological Changes in Patients Receiving Radiation Therapy for Brain Metastases
Background: There are no standardized sets of tests to measure changes in neuropsychological functioning in patients treated for brain metastasis (cancer that has spread beyond the original site to the brain).
- Trial name
- NCT01445483
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Neoplasms, Breast
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
Determine how safe and effective lapatinib is when used to treat patients with ErbB2 overexpressing breast cancer that has spread to the brain and is still progressing there even after radiation treatment using WBRT (whole brain…
- Trial name
- NCT00263588
- Testing
- lapatinib
- Where
- 74 sites in United States, Australia and 15 more
- Volunteers
- 242 people
- Sponsor
- Novartis Pharmaceuticals
Quality of Life, Brain Metastases
Evaluation of the Best Treatment in Terms of Quality of Life for Patients Having a Brain Metastasis
Main Goal : evaluation of quality of life for patient having a brain metastasis and allowed to have either surgery and radiosurgery of the surgical site or only hypofractionned radiosurgery on the lesion.
- Trial name
- OPTMETACER (NCT04358666)
- Testing
- surgery and focal radiosurgery of the surgical bed
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Caen
Male Breast Cancer, Stage IV Breast Cancer
Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer
This phase I trial is studying the side effects and best dose of cediranib maleate when given together with whole brain radiation therapy in treating patients with brain metastases from non-small cell lung cancer.
- Conditions
- Male Breast Cancer, Stage IV Breast Cancer, Stage IV Melanoma, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00937482
- Testing
- cediranib maleate, whole-brain radiation therapy
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.